Biogen Inc. (BIIB)

202.36
NASDAQ
Prev Close 202.54
Day Low/High 198.10 / 203.32
52 Wk Low/High 187.16 / 468.55
Exchange NASDAQ
Shares Outstanding 146.45B
Market Cap 29.66B
P/E Ratio 8.89
Div & Yield N.A. (N.A)
Biotech's Next Big Thing: Biogen

Biotech's Next Big Thing: Biogen

Biogen Idec's earnings will be the next big thing in biotech says TheStreet Sr. Columnist Adam Feuerstein.

Biogen Idec downgraded at Citi

This Is Incredibly Bullish Behavior

This Is Incredibly Bullish Behavior

Most stocks seem unable to stop once propelled higher.

Biotech Makes a Comeback

Biotech Makes a Comeback

Just a natural change in leadership.

Big Pharma Has Lost Its Way

Big Pharma Has Lost Its Way

Many of these firms are pouring money into share buybacks -- instead of their long-term pipelines.

Early-Morning Market Look

Let's take a peek and overnight and morning markets. The beat goes on: S&P futures +2; European markets +; euro +; crude -1.10; gold -2; and 10-year yield 1.68%. Below is today's economic calendar. And here is a list of expected earnings releases fo...

Biogen Idec downgraded at Goldman

Rules of the Game: Biotechs in Rally Mode

Rules of the Game: Biotechs in Rally Mode

Here are two quality names in the sector to watch for a pullback.

National Lemming Day

National Lemming Day

It's the only thing that explains today's action.

The Next Big Thing In Biotech: Large-Cap Earnings

The Next Big Thing In Biotech: Large-Cap Earnings

Earnings from a slew of large-cap biotech players including Celgene, Biogen and Amgen will be the next big thing biotech, Adam Feuerstein, Sr. Columnist for TheStreet, tells Gregg Greenberg.

The Biotech Revaluation Is On

The Biotech Revaluation Is On

These four names in particular have made some stunning moves.

Remember, Everything Gets Exaggerated at First

Remember, Everything Gets Exaggerated at First

Keep that in mind as the market reacts to China this morning.

Health Care Stocks Still Promising

Health Care Stocks Still Promising

Plenty of leadership remains in the health care sector and there's reason to see further potential.

Consider Playing Catch-Up Via Biotech

Consider Playing Catch-Up Via Biotech

Deep-in-the-money call options on these five names could provide a healthy return.

Profit-Takers Still Skimming

Profit-Takers Still Skimming

Here are some names that can be bought during this orderly pullback.

The Real Tech Boom Is Still Just Beginning

The Real Tech Boom Is Still Just Beginning

If you're overly cautious about biotech, you could incur some major opportunity costs.

Biogen Idec numbers raised at UBS

The Next Big Thing In Biotech: Decision Week

The Next Big Thing In Biotech: Decision Week

Ziopharm, AP Pharma and Biogen Idec will headline a very big week of approval decisions, Adam Feuerstein, Sr. Columnist at TheStreet, tells Gregg Greenberg.

Biogen Idec upgraded at Canaccord

RBC Healthcare Conf.

Biogen Idec upgraded at Citigroup

Biogen Idec numbers raised at Jefferies

Before the Bell: Feb. 6

Before the Bell: Feb. 6

Portfolio manager David Peltier previews Wednesday's trading action.

Biogen Idec numbers raised at Jefferies

Blown Away by Transports, Drugs

Blown Away by Transports, Drugs

Not so much by the financials.

Cramer's Catalysts: Heathcare Picks

Cramer's Catalysts: Heathcare Picks

Nicole Urken, Research Associate for Jim Cramer, revisits healthcare stock picks on the back of the JPMorgan Healthcare Conference.